

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	ATION NO. FILING DATE FIRST NAMED INVENTOR		ATTORNEY DOCKET NO. CONFIRMATION		
09/486,293	08/22/2000	JONATHAN A COOPER	14538A-004010US 3432		
7590 07/22/2004			EXAMINER		
N POOR			GEBREYESUS, KAGNEW H		
	OAND TOWNSEND AND DERO CENTER	ART UNIT	PAPER NUMBER		
8TH FLOOR		1652 DATE MAILED: 07/22/2004			
SAN FRANCIS	SCO, CA 94111				

Please find below and/or attached an Office communication concerning this application or proceeding.

, ,								
		Application	on No.	Applicant(s)				
Office Action Summary		09/486,29	93	COOPER ET AL.				
		Examiner	•	Art Unit				
			l Gebreyesus	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHO THE I - Exter after - If the - If NO - Failui Any r	ORTENED STATUTORY PERIOD F MAILING DATE OF THIS COMMUN asions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this comi period for reply specified above is less than thirty (3 period for reply is specified above, the maximum s re to reply within the set or extended period for reply eply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	IICATION. s of 37 CFR 1.136(a). In no ev munication. 30) days, a reply within the stat tatutory period will apply and w y will, by statute, cause the app	ent, however, may a reply be tinutory minimum of thirty (30) darill expire SIX (6) MONTHS from lication to become ABANDONE	mely filed ys will be considered timely in the mailing date of this co	y. ommunication.			
Status								
1)	Responsive to communication(s) file	ed on <u>15 July 2004</u> .						
2a) <u></u>	This action is FINAL . 2b) This action is non-final.							
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
5) 6) 7)	Claim(s) 35 is/are pending in the ap 4a) Of the above claim(s) is/a Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) 1-35 are subject to restrict	are withdrawn from co						
Applicati	on Papers							
10)	The specification is objected to by the transfer of the drawing(s) filed on is/are Applicant may not request that any objected transfer of the oath or declaration is objected to	e: a) accepted or b) ection to the drawing(s) g the correction is require	be held in abeyance. Se red if the drawing(s) is ol	ee 37 CFR 1.85(a). ojected to. See 37 CF				
Priority ι	ınder 35 U.S.C. § 119							
12) <u>□</u> a)	Acknowledgment is made of a claim All b) Some * c) None of: 1. Certified copies of the priority 2. Certified copies of the priority 3. Copies of the certified copies application from the Internationsee the attached detailed Office activities.	y documents have been y documents have been to find the priority documental Bureau (PCT Ru	en received. en received in Applica ents have been receiv le 17.2(a)).	tion No red in this National	Stage			
Attachmen	ut(s) te of References Cited (PTO-892)		4) 🔲 Interview Summar	v (PTO-413)				
2) Notice 3) Information	te of References Cited (PTO-592) te of Draftsperson's Patent Drawing Review (mation Disclosure Statement(s) (PTO-1449 of PTO-1449 of PTO	· · · · · · · · · · · · · · · · · · ·	Paper No(s)/Mail [O-152)			

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- Group I, claims 1-18 are drawn to DNA encoding mammalian Dabl disabled protein 1, or a fragment thereof, vectors, host cells and processes of preparation.
- II. Group II, claims 19-22 are drawn to mammalian disabled protein 1 or a fragment thereof.
- III. Group III, claims 23-32 are drawn to antibodies and binding partners ableto bind to the mammalian disabled protein 1.
- IV. Group IV, claims 33 and 34 are drawn to a method of detecting the presence of, predisposition to develop, a mammalian associated protein 1 associated disease in a subject.
- V. Group V, claim 35 is drawn to a method of screening for a compound that modulates either the level of expression of mammalian disabled protein 1 or the affinity of the mammalian disabled protein 1 to binding partners (Src, Abl, Fyn).

>

Art Unit: 1652

For each of inventions of Groups I – V above, restriction to one of the following is also required under 35 USC 121 and 372. Therefore, election is required of one of inventions of Groups I - V and one of (A) - (C).

- (A) Protein of SEQ ID NO. 3 or a nucleic acid encoding the SEQ ID NO 3.
- (B) Protein of SEQ ID NO. 5 or a nucleic acid encoding the SEQ ID NO 5.
- (C) Protein of SEQ ID NO. 7 or a nucleic acid encoding the SEQ ID NO 7.

The inventions listed as Groups I(A) –V(C) do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCR Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The polynucleotides as claimed in Group I and the proteins in Group II and the antibodies in Group III are each unrelated and chemically distinct entities. The only shared technical feature of these groups is that they all relate to nucleic acids encoding disabled protein 1 (Dab1). However this technical feature is not a special technical feature as defined by PCT Rule 13.2 as it does not define a contribution over the prior art. The following references each teach about the *mdab1* gene: Ware LM et. al., Neuron Vol.19, (239-249) "Aberrent Splicing of a mouse disabled Homolog, *mdab1*, in the scrambler mouse" and Gertler et. et. al., reference BH of applicants IDS of 02/22/00 as well as Brian W. H. et. al., reference DV all teach the *mDab1* gene from various organisms including mammalian *mDab1* from mouse.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirements be traversed (37 CFR 1.143).

Art Unit: 1652

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently inventors is no longer an inventor of at least one claim remaining in the application. Any amendment to inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kagnew H Gebreyesus whose telephone number is 571-272-2937. The examiner can normally be reached on 8:30am-5:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Achutamurthy ponnathapura can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kagnew Gebreyesus Art Unit 1652 RELIGIA E PRIUTY
PRIMATY EXAMINER
GROUP 1900
(600